CINECA IRIS Institutional Research Information System

DI PAOLO, ANTONELLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.998
EU - Europa 4.539
AS - Asia 1.835
AF - Africa 191
SA - Sud America 77
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 2
Totale 19.669
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.702
IT - Italia 1.809
SE - Svezia 897
CN - Cina 824
BG - Bulgaria 477
SG - Singapore 368
DE - Germania 348
CA - Canada 272
GB - Regno Unito 240
VN - Vietnam 214
TR - Turchia 174
FI - Finlandia 159
FR - Francia 139
UA - Ucraina 136
CI - Costa d'Avorio 100
IN - India 77
BE - Belgio 67
CH - Svizzera 55
RU - Federazione Russa 51
HK - Hong Kong 47
BR - Brasile 44
GR - Grecia 37
NG - Nigeria 35
AU - Australia 23
IR - Iran 22
NL - Olanda 19
PL - Polonia 19
JP - Giappone 18
SN - Senegal 18
EG - Egitto 17
ES - Italia 17
KR - Corea 17
MX - Messico 16
AT - Austria 15
ID - Indonesia 15
IE - Irlanda 15
TH - Thailandia 11
CO - Colombia 8
AR - Argentina 7
CZ - Repubblica Ceca 7
DK - Danimarca 7
DZ - Algeria 7
EC - Ecuador 7
MY - Malesia 7
PH - Filippine 7
JO - Giordania 6
RS - Serbia 5
BJ - Benin 4
IQ - Iraq 4
NZ - Nuova Zelanda 4
PE - Perù 4
RO - Romania 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
BF - Burkina Faso 3
BO - Bolivia 3
CL - Cile 3
LT - Lituania 3
PK - Pakistan 3
AE - Emirati Arabi Uniti 2
CR - Costa Rica 2
CU - Cuba 2
EU - Europa 2
HU - Ungheria 2
KW - Kuwait 2
MA - Marocco 2
NI - Nicaragua 2
NO - Norvegia 2
PA - Panama 2
TG - Togo 2
TW - Taiwan 2
AM - Armenia 1
AZ - Azerbaigian 1
CY - Cipro 1
EE - Estonia 1
HR - Croazia 1
IL - Israele 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
NP - Nepal 1
PT - Portogallo 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UG - Uganda 1
UY - Uruguay 1
Totale 19.669
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.783
Houston 1.606
Ann Arbor 1.492
Fairfield 1.433
Chandler 787
Ashburn 764
Seattle 622
Wilmington 504
Cambridge 492
Sofia 477
Milan 408
Beijing 299
New York 293
Serra 293
Ottawa 252
Boardman 240
Princeton 231
Lawrence 192
Medford 174
Jacksonville 169
Izmir 158
Singapore 157
Nanjing 136
Dearborn 130
Des Moines 118
Dong Ket 103
Abidjan 100
Florence 81
Washington 80
Pisa 79
San Diego 78
Brussels 62
Redwood City 60
Boulder 58
Nanchang 58
London 57
Rome 52
Frankfurt am Main 50
Kunming 49
Bern 48
Chicago 45
Ogden 45
Hong Kong 44
Falls Church 37
Lagos 35
Norwalk 33
Shenyang 33
Bremen 31
Hebei 29
Changsha 28
Pune 28
Los Angeles 25
Jiaxing 24
Dallas 21
Hefei 20
Jüchen 20
Dakar 18
Auburn Hills 17
Düsseldorf 16
Vienna 14
Warsaw 14
Bologna 13
Guangzhou 13
Livorno 13
Phoenix 13
Helsinki 12
Lancaster 12
Seacroft 10
Tianjin 10
Detroit 9
Gela 9
Jakarta 9
Lucca 9
Nürnberg 9
Shanghai 9
Torino 9
Indiana 8
Jinan 8
Orange 8
San Francisco 8
Cairo 7
Chengdu 7
Council Bluffs 7
Edinburgh 7
Groningen 7
Hangzhou 7
Shenzhen 7
Toronto 7
Amman 6
Calci 6
Cutrofiano 6
Kilburn 6
Kocaeli 6
Lanzhou 6
Ludwigsburg 6
Madrid 6
Seelze 6
Stockholm 6
Zhengzhou 6
Al Mansurah 5
Totale 15.120
Salva come PNG Salva come JPEG
Nome #
DECONTAMINAZIONE CON GENTAMICINA ORALE NEI PAZIENTI CON COLONIZZAZIONE INTESTINALE DA KLEBSIELLA PNEUMONIAE PRODUTTRICE DI KPC IN CORSO DI EPIDEMIA 477
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity 304
A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma 209
Determination of mitotane and principal metabolite by a simple HPLC-UV method and its validation in human plasma sample 198
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 188
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia 170
IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA 160
An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients 157
Pharmacogenetics in Oncology 155
ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. 153
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 152
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 151
5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer 149
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 146
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity 145
The role of thymidylate synthase as a molecular biomarker 142
Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study 138
Personalized medicine of monoclonal antibodies in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and beyond 138
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. 135
A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference Mass Spectrometry 135
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 134
Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis 134
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 134
Chronic administration of suramin induces neurotoxicity in rats 133
Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers 133
Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin 132
Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells 131
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. 131
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role 130
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma 130
Linezolid for endocarditis: a case series of 14 patients 129
The pharmacological bases of the antiangiogenic activity of paclitaxel 129
Methods: For studying pharmacogenetic profiles of combination chemotherapeutic drugs 129
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 129
Impact of locoregional approaches to liver metastases in patients with colorectal cancer 128
Administration interval and daptomycin toxicity: a case report of rhabdomyolysis 128
ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients 128
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib 128
null 127
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 127
Genotype A1/A2 associated with neuroleptic malignant syndrome 126
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 125
Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers 125
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 125
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 125
Procedimento attuato per mezzo di un elaboratore per la determinazione dei tempi di ritenzione e dei valori di concentrazione di analiti in una miscela 125
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview 124
Appropriateness of repetitive therapeutic drug monitoring and laboratory turn around time 122
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 121
Serotonin syndrome and the T102-->C polymorphism of the 5-HT2A receptor: a case report 120
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 119
null 117
Pharmacogenetics of Antiangiogenic Therapy 115
5-Fluorouracil exposure in adjuvant chemotherapy regimens is significantly related to disease free survival in colorectal cancer patients 114
Different recommendations for daptomycin dosing over time in patients with severe infections 114
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 114
A new HPLC-UV method compared with HPLC-MS for daptomycin levels in human plasma samples 114
Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal 113
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 113
Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients 113
Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo 113
Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib 112
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 112
Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines 110
Linezolid in the central nervous system: Comparison between cerebrospinal fluid and plasma pharmacokinetics 110
Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients 110
A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment 110
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer 109
Biologic basis of ovarian metastasis of colorectal cancer 109
Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections 109
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 109
Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges 109
Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: A preclinical study 109
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer 108
Ziprasidone as Adjunctive Therapy in Severe Bipolar Patients Treated with Clozapine 107
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 107
Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia 107
Predicting survival with artificial neural networks 106
Personalized medicine in Europe: not yet personal enough? 106
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 106
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib 106
Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily 105
Prognostic value of CD133 caused by mutant K-Ras and B-Raf 105
In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma 104
Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling 104
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed 103
Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis 103
Precision medicine in lymphoma by innovative instrumental platforms 103
Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid 102
Irinotecan in 5-fluorouracil-refractory colorectal cancer 101
Liposomal anticancer therapy: pharmacokinetic and clinical aspects 101
The 5-Fluorouracil Test Dose 101
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications 101
First Case of Trichoderma longibrachiatum CIED (Cardiac Implantable Electronic Device)-Associated Endocarditis in a Non-immunocompromised Host: Biofilm Removal and Diagnostic Problems in the Light of the Current Literature 101
Genetic determinants in the study of colorectal cancer 98
Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate 98
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 98
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6,dihydrouracil after conventional and reduced test dose in cancer patients 97
Prognostic value of CD133 caused by mutant K-RAS and B-RAF letter. 97
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 97
Totale 12.793
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.949
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.949
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.907 0 0 0 261 397 521 454 322 366 245 264 77
2020/20211.824 127 147 159 84 150 137 76 167 200 160 109 308
2021/20222.361 69 134 90 128 378 385 86 125 93 95 131 647
2022/20232.747 390 318 181 232 301 410 39 210 453 22 168 23
2023/20242.101 229 237 253 123 269 371 95 104 51 50 87 232
2024/2025413 41 243 78 51 0 0 0 0 0 0 0 0
Totale 20.164